The currently adopted treatment for active chronic hepatitis, based on the results of a number of controlled trials (Cook et al., 1971; Murray-Lyon et al., 1973; Summerskill et al., 1975) , is with corticosteroids, often in combination with azathioprine (Summerskill et al., 1975) . Although this treatment reduces the overall mortality and suppresses the inflammatory component of the liver lesion, there is no evidence to suggest that it affects established cirrhosis. Furthermore, the side-effects from both corticosteroids and azathioprine have been a problem in these series. Over the last eight years a number of workers, mainly from continental Europe, have reported promising results with D-penicllamine, but so far no controlled trials have been reported. In the controlled trial reported here, the value of D-penicillamine was compared with prednisone in the maintenance therapy of active chronic hepatitis, once the disease had been brought under control initially with larger doses of corticosteroids. ' toxicity side-effects disappeared when the drug was stopped. Only two patients were withdrawn from the D-penicillamine group because of lack of control of disease activity, and seven developed drug toxicity side-effects. The nine patients from this group who remained in the trial showed no deterioration in liver function tests at the end of one year's continuous treatment.
In contrast, only one patient from the prednisone group was withdrawn because of drug toxicity sideeffects, but four were withdrawn because the disease became out of control and one because of the development of carcinomatosis. Although the reasons for withdrawal were different in the two groups, these differences did not achieve statistical significance, and neither did the total number of withdrawals.
An analysis of the mean values for serum bilirubin, aspartate transaminase, and a globulin levels of the patients who remained in the two treatment groups after one year's continuous treatment also showed no significant statistical differences. The initial values for these patients on entry to the trial were also essentially similar. The mean serum caeruloplasmin in the D-penicillamine group was lower after a year's treatment than on entry, but this did not reach statistical significance (Table 2) .
A comparison of patients with or without cirrhosis, or HBsAg, within and between the two groups, showed no significant differences in the number of Controlled trial of synthetic D-penicillamine andprednisone (Summerskill et al., 1975 (Huskisson et al., 1976) , although it is known for its inhibitory effect on collagen synthesis, increasing the ratio of uncrosslinked fibrils (Nimni and Bavetta, 1965; Harris and Sjoerdsma, 1966; Francis et a!., 1973 (Goldberg et al., 1963; Yonis and Karp, 1963; Sternlieb, 1966; Rosenberg and Hayslett, 1967; Crawhall and Watts, 1968) are perhaps the most serious, although only one case was seen in the present series and this was reversed when the drug was withdrawn. A wide variety of skin lesions and occasionally fatal blood dyscrasias have also been described (Walshe, 1968; Andrews et al., 1973) . Loss of taste acuity or a metallic taste in the mouth are common, occurring in up to a third of patients (Scheinberg, 1968; Andrews et a!., 1973) but may be reversed with copper sulphate. Side-effects may be minimised by starting with a low dosage, as was done in the present series, and recent studies in rheumatoid arthritis have also shown that doses as low as 600 mg daily produce just as good a therapeutic effect as 1200 mg with fewer side-effects (Dixon et a!., 1975) .
In conclusion, it is clear that, because of the frequency of toxicity side-effects, D-penicillamine, at least in the present dosage, cannot be considered to be the treatment of choice in the maintenance therapy of patients with active chronic hepatitis. However, if prednisone (with or without azathioprine) becomes contraindicated because of the development of complications such as diabetes, osteoporosis, gastric ulceration, etc (or of leucopenia or neutropenia attributable to azathioprine), or if the disease fails to come under control, it would seem on the basis of our findings to be a useful alternative drug.
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